The advisory board will help strengthen relationships with key customers and partners.
SAN FRANCISCO – (December 02, 2021) – Aizon, an enterprise AI software application provider, announced today the creation of a Strategic Advisory Board (SAB) made up of four world-renowned executives from the pharmaceutical and healthcare industries. New members include Michele D’Alessandro, Jerh Collins, Dr. Antonio Moreira and Matthias Pohl.
The Board is engaged in support of Aizon’s mission to enable biopharmaceutical companies to transform their manufacturing operations with the use of advanced analytics, artificial intelligence (AI), machine learning (ML), iOT and other smart factory technologies. Its members will provide strategic counsel to Aizon’s executive and product teams while providing insights to help drive customer’s adoption of Aizon’s GxP based platform and applications.
“We have a real and very timely opportunity to help pharmaceutical and biotech companies begin or accelerate their digital transformation journeys toward attaining Pharma 4.0 capabilities through a measured and strategic approach,” said John Vitalie, CEO, Aizon. “We look forward with excitement to their future contributions to the achievement of Aizon’s strategic objectives and to applying their industry expertise to help us address our customer most critical production challenges and to bring break-through capabilities to them in ways that can generate significant value as they accelerate their digital transformation."
The four members of the board include:
- Michele D'Alessandro is most recently (5/2021) Vice President and CIO of Manufacturing IT at Merck. In this role, she provided strategic leadership, oversight and delivery of information technology and digital solutions for the Merck Manufacturing Division. She currently runs her own consultancy business, providing advisory services with an emphasis on IT transformation and Women in STEM.
- As Chief Culture Officer for Novartis, Jerh Collins, is responsible for scaling the company’s people and culture initiatives while integrating culture in the flow of daily work. He was previously Head of Global Chemical Operations & Anti-infectives at Novartis where he was responsible for the Global Small Molecules and Anti-infectives site network.
- Antonio (Tony) Moreira, PhD is Vice Provost for Academic Affairs at the University of Maryland and Chair of the Board of the ISPE Foundation. Tony has over 30 years of experience in the biopharma sector and spent nearly 10 years in management positions with International Flavors and Fragrances and Schering-Plough Corp. (now Merck).
- Partner at InterPharmaLink, Matthias Pohl brings extensive experience in phases of start-up, stabilization, restructuring and expansions. He was previously Global Head of Health, Safety, Environment and Business Continuity Management at Novartis and Head of Global Quality at Sandoz.
For more information on the Aizon Strategic Advisory Board, visit: https://aizonai.stage.site/about/.
About Aizon
Aizon is an AI software provider that transforms manufacturing operations with the use of advanced analytics, artificial intelligence, and other smart factory technologies focused on optimizing production within highly regulated industries. The Aizon AI platform seamlessly integrates unlimited sources of structured and unstructured data to deliver actionable insights across all manufacturing sites. Aizon offers an intuitive way to gain meaningful operational intelligence by enabling real-time visibility and predictive insights in a GxP compliant manner with end-to-end data integrity.